|
US2007232697A1
|
|
Method for preparing free base compositions and formulations thereof
|
|
US2007231390A1
|
|
Formulations including hygroscopic compounds
|
|
AU2005239716A1
|
|
Controlled Release Metformin Compositions
|
|
WO2006044077A2
|
|
Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
|
|
WO2008100240A2
|
|
Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
|
|
US2007231386A1
|
|
Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
|
|
US2006034922A1
|
|
Controlled release metformin compositions
|
|
WO2005107750A1
|
|
Controlled release metformin compositions
|
|
US2005215621A1
|
|
Method of treating amyloid beta precursor disorders
|
|
TW200529831A
|
|
Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
|
US2005095288A1
|
|
Decongestant and expectorant tablets
|
|
US2006065556A1
|
|
Packaging system and method of use
|
|
US7051606B2
|
|
Dosage form holder device and methods for immersion testing
|
|
WO2004066924A2
|
|
Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
|
|
WO2004026241A2
|
|
Multistage formulation containing a biguanide and thiazolidindione derivatives
|
|
EP1723948A1
|
|
Controlled release compositions of biguanide with less side effects and treatment regimen thereof
|
|
US6866866B1
|
|
Controlled release metformin compositions
|
|
US6790459B1
|
|
Methods for treating diabetes via administration of controlled release metformin
|
